In the past decade, a dramatic shift has been witnessed in cancer therapy in C hina.
Although traditional cytotoxic chemotherapy still remains the treatment of choice for many …

In the last several years, we have made slow but steady progress in developing new
treatment strategies for patients with lung cancer. The use of molecularly targeted therapy …

Recent advances in methods of genomic profiling have accelerated our understanding of
the biology of oncologic diseases. Accumulating evidence suggests that both histology and …

Abstract Treatment of progressive non-small cell lung cancer (NSCLC) has advanced
remarkably, due in part to the development of targeted therapies. Several gene alterations …

In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following
molecular profiling has dramatically changed the way advanced adenocarcinoma is treated …

Lung cancer remains the leading cause of cancer related death worldwide. Despite broad
advances in diagnostics and therapy, the five-year overall survival for patients with …

Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an
incidence that increases yearly across the world. The introduction in clinical practice of …

Simple Summary Non-small cell lung cancer treatment has undergone a revolution in the
past decade owing to the discovery of mutations that drive carcinogenesis and the …

Lung cancer, of which non-small lung cancer is the most common subtype, represents the
leading cause of cancer related-death worldwide. It is now recognized that a significant …

Lung cancer is the leading cause of cancer-related mortality worldwide. The discovery of
tyrosine kinase inhibitors effectively targeting EGFR mutations in lung cancer patients in …